Gregory Smith Biography and Net Worth

EVP of Medtronic


Greg Smith is Executive Vice President, Global Operations and Supply Chain at Medtronic. He is responsible for the performance and integration of all aspects of the company’s operations including Manufacturing, Supply Chain, Supply Management, Operational Excellence and Transformation, Enterprise Risk and Facilities, and Operations Quality.

Before joining Medtronic in April 2021, Greg was the Executive Vice President of U.S. Supply Chain at Walmart, one of the world’s largest and most complex supply chains. Greg transformed Walmart’s supply chain to be best in class, developing and implementing a comprehensive strategy that drove sales, achieved operational excellence, reduced costs, and that created an engaging, enabling, and empowering work environment.

Greg is deeply committed to diversity, equality, and the belief that a diverse workplace where everyone feels included results in stronger teams and the highest level of service to our patients, customers, and employees. He was recognized as a 2020 Diversity Leader by Diversity Journal(opens new window).

Before joining Walmart, Greg was Senior Vice President, Global Operations at The Goodyear Tire & Rubber Company, where he was responsible for 52 manufacturing facilities across four business units around the world. He successfully led the company’s global optimization program and implemented an enterprise manufacturing operating system, a global procurement program, and an enterprise planning and logistics approach.

In his more than 35 years of supply chain and operations experience, Greg has also transformed manufacturing, procurement, and logistics programs at companies including ConAgra Foods, United Signature Foods, VDK Frozen Foods, and Quaker Oats.

Greg earned his bachelor’s degree in finance from the University of Tennessee, Knoxville, and he currently serves on the university’s Global Supply Chain Institute and College of Business advisory board. He serves on the GS1 Management Board and is a member of its Board Committee for Healthcare. Additionally, he serves as co-lead of the Supply Chain vertical of the Action Collaborative for Decarbonization for the National Academy of Medicine, and he is a member of the Gartner Supply Chain Advisory Board.

What is Gregory L. Smith's net worth?

The estimated net worth of Gregory L. Smith is at least $3.79 million as of August 23rd, 2023. Mr. Smith owns 46,723 shares of Medtronic stock worth more than $3,785,965 as of December 20th. This net worth evaluation does not reflect any other assets that Mr. Smith may own. Learn More about Gregory L. Smith's net worth.

How do I contact Gregory L. Smith?

The corporate mailing address for Mr. Smith and other Medtronic executives is 20 ON HATCH LOWER HATCH STREET, DUBLIN L2, D02. Medtronic can also be reached via phone at (531) 438-1700 and via email at [email protected]. Learn More on Gregory L. Smith's contact information.

Has Gregory L. Smith been buying or selling shares of Medtronic?

Gregory L. Smith has not been actively trading shares of Medtronic in the last ninety days. Most recently, Gregory L. Smith sold 10,000 shares of the business's stock in a transaction on Wednesday, August 23rd. The shares were sold at an average price of $83.84, for a transaction totalling $838,400.00. Following the completion of the sale, the executive vice president now directly owns 46,723 shares of the company's stock, valued at $3,917,256.32. Learn More on Gregory L. Smith's trading history.

Who are Medtronic's active insiders?

Medtronic's insider roster includes Richard Anderson (Director), Michael Coyle (EVP), Gary Ellis (EVP), Hooman Hakami (EVP), Bryan Hanson (EVP), Omar Ishrak (Chairman), Richard Kuntz (SVP), Bradley Lerman (SVP), John Liddicoat (EVP), Michael Marinaro (EVP), Geoffrey Martha (Chairman of the Board & CEO), Karen Parkhill (CFO), Sean Salmon (EVP), Gregory Smith (EVP), Carol Surface (SVP), Rob Ten Hoedt (EVP), Brett Wall (EVP), Brett Wall (EVP), and Robert White (EVP). Learn More on Medtronic's active insiders.

Are insiders buying or selling shares of Medtronic?

During the last year, insiders at the medical technology company sold shares 3 times. They sold a total of 50,662 shares worth more than $4,285,162.92. The most recent insider tranaction occured on June, 7th when CEO Geoffrey Martha sold 19,113 shares worth more than $1,601,096.01. Insiders at Medtronic own 0.2% of the company. Learn More about insider trades at Medtronic.

Information on this page was last updated on 6/7/2024.

Gregory L. Smith Insider Trading History at Medtronic

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/23/2023Sell10,000$83.84$838,400.0046,723View SEC Filing Icon  
See Full Table

Gregory L. Smith Buying and Selling Activity at Medtronic

This chart shows Gregory L Smith's buying and selling at Medtronic by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Medtronic Company Overview

Medtronic logo
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.
Read More

Today's Range

Now: $81.03
Low: $79.80
High: $81.26

50 Day Range

MA: $86.90
Low: $79.99
High: $92.27

2 Week Range

Now: $81.03
Low: $75.96
High: $92.68

Volume

10,706,827 shs

Average Volume

6,272,357 shs

Market Capitalization

$103.90 billion

P/E Ratio

24.78

Dividend Yield

3.44%

Beta

0.82